Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 129, Issue 9
March 2 2017
Issue Cover

Table of Contents

EDITORIAL

Introduction to the review series on T-cell malignancies
Clinical Trials & Observations
Laurie H. Sehn,Jean Soulier
View Articletitled, Introduction to the review series on T-cell malignancies

BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
3 + 7 + FLT3 inhibitors: 1 + 1 ≠ 2
Clinical Trials & Observations
Richard M. Stone
View Articletitled, 3 + 7 + FLT3 inhibitors: 1 + 1 ≠ 2
INSIDE BLOOD COMMENTARY
Targeting precursor BCR signaling in ALL
Ilaria Iacobucci
View Articletitled, Targeting precursor BCR signaling in ALL
INSIDE BLOOD COMMENTARY
Immune reconstitution and remission in CML
David A. Scheinberg
View Articletitled, Immune reconstitution and remission in CML
INSIDE BLOOD COMMENTARY
Complement factors (H) into thrombosis
Michael Holinstat
View Articletitled, Complement factors (H) into thrombosis
INSIDE BLOOD COMMENTARY
Stressed platelets ASK1 for a MAPK
Robert Flaumenhaft
View Articletitled, Stressed platelets ASK1 for a MAPK
INSIDE BLOOD COMMENTARY
GVHD: ferocity affects feracitas
Pavan Reddy
View Articletitled, GVHD: ferocity affects <em>feracitas</em>

REVIEW SERIES

Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1–infected T cells
Toshiki Watanabe
View Articletitled, Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1–infected T cells
LGL leukemia: from pathogenesis to treatment
Clinical Trials & Observations
Thierry Lamy,Aline Moignet,Thomas P. Loughran, Jr
View Articletitled, LGL leukemia: from pathogenesis to treatment
Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma
Clinical Trials & Observations
Matthew A. Lunning,Julie M. Vose
View Articletitled, Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma
Peripheral T-cell lymphoma, not otherwise specified
Clinical Trials & Observations
Alessandro Broccoli,Pier Luigi Zinzani
View Articletitled, Peripheral T-cell lymphoma, not otherwise specified
The genetics and molecular biology of T-ALL
Tiziana Girardi,Carmen Vicente,Jan Cools,Kim De Keersmaecker
View Articletitled, The genetics and molecular biology of T-ALL
The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia
Marta Sanchez-Martin,Adolfo Ferrando
View Articletitled, The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia
Management of adults with T-cell lymphoblastic leukemia
Clinical Trials & Observations
David I. Marks,Clare Rowntree
View Articletitled, Management of adults with T-cell lymphoblastic leukemia

CLINICAL TRIALS AND OBSERVATIONS

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
Clinical Trials & Observations
Steven Knapper,Nigel Russell,Amanda Gilkes,Robert K. Hills,Rosemary E. Gale,James D. Cavenagh,Gail Jones,Lars Kjeldsen,Michael R. Grunwald,Ian Thomas,Heiko Konig,Mark J. Levis,Alan K. Burnett
View Articletitled, A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
Supplemental data

LYMPHOID NEOPLASIA

Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK
Ekaterina Kim,Christian Hurtz,Stefan Koehrer,Zhiqiang Wang,Sriram Balasubramanian,Betty Y. Chang,Markus Müschen,R. Eric Davis,Jan A. Burger
View Articletitled, Ibrutinib inhibits pre-BCR<sup>+</sup> B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK
Supplemental data

MYELOID NEOPLASIA

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors
Amy Hughes,Jade Clarson,Carine Tang,Ljiljana Vidovic,Deborah L. White,Timothy P. Hughes,Agnes S. M. Yong
View Articletitled, CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors
Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

Lysophosphatidic acid converts monocytes into macrophages in both mice and humans
Brief Report
Rashmi Ray,Vivek Rai
View Articletitled, Lysophosphatidic acid converts monocytes into macrophages in both mice and humans
Supplemental data

PLATELETS AND THROMBOPOIESIS

Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation
Yoshiyasu Ueda,Imran Mohammed,Delu Song,Damodar Gullipalli,Lin Zhou,Sayaka Sato,Yuan Wang,Shuchi Gupta,Zhongjian Cheng,Hong Wang,Jialing Bao,Yingying Mao,Lawrence Brass,X. Long Zheng,Takashi Miwa,Matthew Palmer,Joshua Dunaief,Wen-Chao Song
View Articletitled, Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation
Supplemental data
Ask1 regulates murine platelet granule secretion, thromboxane A2 generation, and thrombus formation
Meghna U. Naik,Pravin Patel,Randall Derstine,Ramya Turaga,Xi Chen,Kalyan Golla,Keith B. Neeves,Hidenori Ichijo,Ulhas P. Naik
View Articletitled, Ask1 regulates murine platelet granule secretion, thromboxane A<sub>2</sub> generation, and thrombus formation

THROMBOSIS AND HEMOSTASIS

Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events
Clinical Trials & Observations
Meir Preis,Julianna Hirsch,Antonio Kotler,Ahmad Zoabi,Nili Stein,Gad Rennert,Walid Saliba
View Articletitled, Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events

TRANSPLANTATION

Graft-versus-host disease targets ovary and causes female infertility in mice
Sonoko Shimoji,Daigo Hashimoto,Hidetsugu Tsujigiwa,Kohta Miyawaki,Koji Kato,Shuichiro Takahashi,Reiki Ogasawara,Takashi Jiromaru,Hiromi Iwasaki,Toshihiro Miyamoto,Koichi Akashi,Takanori Teshima
View Articletitled, Graft-versus-host disease targets ovary and causes female infertility in mice
Supplemental data

LETTER TO BLOOD

ACE inhibitors and cytoreductive therapy in polycythemia vera
Clinical Trials & Observations
Tiziano Barbui,Arianna Masciulli,Arianna Ghirardi,Alessandra Carobbio
View Articletitled, ACE inhibitors and cytoreductive therapy in polycythemia vera
Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?
Clinical Trials & Observations
Mathieu Leclerc,on behalf of the French Society of Bone Marrow Transplantation and Cell Therapy,Régis Peffault de Latour,on behalf of the French Society of Bone Marrow Transplantation and Cell Therapy,Mauricette Michallet,on behalf of the French Society of Bone Marrow Transplantation and Cell Therapy,Didier Blaise,on behalf of the French Society of Bone Marrow Transplantation and Cell Therapy,Patrice Chevallier,on behalf of the French Society of Bone Marrow Transplantation and Cell Therapy,Pierre-Simon Rohrlich,on behalf of the French Society of Bone Marrow Transplantation and Cell Therapy,Pascal Turlure,on behalf of the French Society of Bone Marrow Transplantation and Cell Therapy,Stéphanie Nguyen,on behalf of the French Society of Bone Marrow Transplantation and Cell Therapy,Fabrice Jardin,on behalf of the French Society of Bone Marrow Transplantation and Cell Therapy,Ibrahim Yakoub-Agha,on behalf of the French Society of Bone Marrow Transplantation and Cell Therapy,Sébastien Maury,on behalf of the French Society of Bone Marrow Transplantation and Cell Therapy
View Articletitled, Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?
Supplemental data

BLOOD WORK

Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation
Ibrahim Aldoss,Joo Y. Song
View Articletitled, Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation
All Issues

Advertisement intended for health care professionals

Licking the wound with procoagulant vesicles
Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study
CAR T-cells in autoimmunity: game changer or stepping stone?
Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH
How I treat quantitative fibrinogen disorders

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals